Can speech therapy help those losing their words? new trial aims to find out

NCT ID NCT06191198

Recruiting now Symptom relief Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two types of speech therapy for adults with mild-to-moderate primary progressive aphasia, a condition that slowly impairs language. Researchers will compare the therapies in 200 participants to see which better improves communication and reduces caregiver burden. The goal is to find an effective, evidence-based treatment to help people maintain their ability to talk and connect with others.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: speech-language therapy (Communication Bridge™)
What this could lead to: If successful, this could provide an effective speech therapy program to help people with primary progressive aphasia communicate better and improve quality of life.
What could go wrong: This is a Phase 2 trial with 200 participants, so results are still preliminary. The therapy may not work for everyone, and benefits might be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE APHASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease aphasia Communication dementia frontotemporal dementia primary progressive aphasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY PROGRESSIVE APHASIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

University of Chicago - American School Building
RECRUITING

Chicago, Illinois, 60637, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.